HUYABIO International, LLC.

Bakersfield, California

OncologyPhase III

What changed

Phase III trial registered: Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

9mo agoTrial registeredSep 24, 2025Source filing (opens the source filing in a new tab)

Momentum

51no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R01 · $338k · non-dilutive
Jul 1, 2024
UNIVERSITY OF CALIFORNIA-IRVINE · PI LEE, GRACE YUH CHWEN · NIDDK · award ends Apr 30, 2028 · Dietary impacts on organismal health through altering epigenetic silencing of transposable elements
NIH RePORTER · NIH RePORTER 11117109 (opens the source filing in a new tab)
Grant
R35 · $382k · non-dilutive
Sep 1, 2021
UNIVERSITY OF CALIFORNIA-IRVINE · PI LEE, GRACE YUH CHWEN · NIGMS · award ends Jul 15, 2026 · How transposable elements drive genome evolution through epigenetic mechanisms
NIH RePORTER · NIH RePORTER 11121085 (opens the source filing in a new tab)
Trial
PHASE3 registered
Aug 12, 2021
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis · ACTIVE_NOT_RECRUITING · sponsor: HUYABIO International, LLC. · Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
ClinicalTrials.gov · NCT04674683 (opens the source filing in a new tab)
Grant
R01 · $421k · non-dilutive
Jun 1, 2021
WEILL MEDICAL COLL OF CORNELL UNIV · PI LEE, GUINEVERE · NIAID · award ends May 31, 2027 · Characterization of Non-subtype B HIV-1 Reservoirs and its Association with Longitudinal Clinical Outcomes
NIH RePORTER · NIH RePORTER 11080357 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the trial record at 0.27{"reasons":["same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase III trial registered: Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
9mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Dietary impacts on organismal health through altering epigenetic silencing of transposable elements
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.4M · How transposable elements drive genome evolution through epigenetic mechanisms
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Characterization of Non-subtype B HIV-1 Reservoirs and its Association with Longitudinal Clinical Outcomes
May 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R01 · $338k · non-dilutive

R35 · $382k · non-dilutive

PHASE3 registered

R01 · $421k · non-dilutive